Differential roles of Alzheimer's disease plasma biomarkers in stepwise biomarker-guided diagnostics

被引：0

作者：

Jang, Hyemin ^{[1
]}

Shin, Daeun ^{[2
]}

Yoo, Heejin ^{[2
]}

Zetterberg, Henrik ^{[3
,4
,5
,6
,7
,8
]}

Blennow, Kaj ^{[3
,4
,9
,10
,11
,12
]}

Gonzalez-Ortiz, Fernando ^{[3
,4
]}

Ashton, Nicholas J. ^{[3
,13
,14
,15
,16
]}

Day, Theresa A. ^{[17
]}

Lee, Eun Hye ^{[2
]}

Yun, Jihwan ^{[18
]}

Na, Duk L. ^{[2
]}

Kim, Hee Jin ^{[2
,19
,20
,21
]}

Kang, Sung Hoon ^{[22
]}

Kim, Ko Woon ^{[23
]}

Kim, Si Eun ^{[24
]}

Kim, Yeo Jin ^{[25
]}

Kim, Yeshin ^{[26
]}

Kim, Jaeho ^{[27
]}

Kim, Chi-Hun ^{[28
]}

Chun, Min Young ^{[29
,30
]}

Jung, Na Yeon ^{[31
]}

Cho, Soo Hyun ^{[32
]}

Kim, Jun Pyo ^{[2
]}

Seo, Sang Won ^{[2
,19
,20
,21
]}

K-ROAD Study Grp

机构：

[1] Seoul Natl Univ, Coll Med, Dept Neurol, Seoul Natl Univ Hosp, Seoul, South Korea

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, 81 Irwon Ro, Seoul 06351, South Korea

[3] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Sahlgrenska Acad, Molndal, Sweden

[4] Sahlgrens Univ Hosp, Clin Neurochem Lab, Gothenburg, Sweden

[5] UCL, Dept Neurodegenerat Dis, Inst Neurol, Queen Sq, London, England

[6] UCL, UK Dementia Res Inst, London, England

[7] Hong Kong Ctr Neurodegenerat Dis, Clear Water Bay, Hong Kong, Peoples R China

[8] Univ Wisconsin Madison, Wisconsin Alzheimers Dis Res Ctr, Univ Wisconsin Sch Med & Publ Hlth, Madison, WI USA

[9] Sorbonne Univ, Pitie Salpetriere Hosp, Paris Brain Inst, ICM, Paris, France

[10] Univ Sci & Technol China, Affiliated Hosp USTC 1, Inst Aging & Brain Disorders, Hefei, Peoples R China

[11] Univ Sci & Technol China, Inst Aging & Brain Disorders, Dept Neurol, Hefei, Peoples R China

[12] USTC, Affiliated Hosp 1, Hefei, Peoples R China

[13] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Inst Psychiat Psychol & Neurosci, De Crespigny Pk, London, England

[14] South London & Maudsley NHS Fdn Trust, NIHR Biomed Res Ctr Mental Hlth, De Crespigny Pk, London, England

[15] South London & Maudsley NHS Fdn, Biomed Res Unit Dementia, De Crespigny Pk, London, England

[16] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway

[17] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN USA

[18] Soonchunhyang Univ, Bucheon Hosp, Dept Neurol, Bucheon Si, Gyeonggi Do, South Korea

[19] Samsung Med Ctr, Alzheimers Dis Convergence Res Ctr, Seoul, South Korea

[20] Sungkyunkwan Univ, Dept Hlth Sci & Technol, SAIHST, Seoul, South Korea

[21] Samsung Med Ctr, Neurosci Ctr, Seoul, South Korea

[22] Korea Univ, Coll Med, Dept Neurol, Guro Hosp, Seoul, South Korea

[23] Jeonbuk Natl Univ, Med Sch & Hosp, Dept Neurol, Jeonju Si, South Korea

[24] Inje Univ, Coll Med, Haeundae Paik Hosp, Dept Neurol, Busan, South Korea

[25] Hallym Univ, Coll Med, Kangdong Sacred Heart Hosp, Dept Neurol, Seoul, South Korea

[26] Kangwon Natl Univ, Sch Med, Kangwon Natl Univ Hosp, Dept Neurol, Chuncheon Si, Gangwon Do, South Korea

[27] Hallym Univ, Coll Med, Dongtan Sacred Heart Hosp, Dept Neurol, Seoul, South Korea

[28] Hallym Univ, Coll Med, Dept Neurol, Sacred Heart Hosp, Anyang Si 431070, Gyeonggi Do, South Korea

[29] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea

[30] Yonsei Univ Hlth Syst, Yongin Severance Hosp, Dept Neurol, Yongin, Gyeonggi Do, South Korea

[31] Pusan Natl Univ, Yangsan Hosp, Res Inst Convergence Biomed Sci & Technol, Dept Neurol, Yangsan Si, Gyeongsangnam D, South Korea

[32] Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Dept Neurol, Gwangju, South Korea

来源：

ALZHEIMERS & DEMENTIA | 2025年 / 21卷 / 02期

基金：

瑞典研究理事会; 新加坡国家研究基金会;

关键词：

Alzheimer's disease; neurofilament light chain; positron emission tomography; plasma biomarker; p-tau217; PHOSPHORYLATED TAU 181; NEUROFILAMENT LIGHT; BLOOD BIOMARKERS; PROTEIN;

D O I：

10.1002/alz.14526

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

INTRODUCTION This study aimed to investigate the differential roles of various plasma biomarkers in a stepwise diagnostic strategy for Alzheimer's disease (AD). METHODS A total of 2984 participants, including 666 cognitively unimpaired (CU), 2032 with Alzheimer's clinical syndrome (ACS), and 286 non-ACS individuals, were recruited. Plasma amyloid beta (A beta) 42/40, four phosphorylated tau (p-tau) epitopes, glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) levels were measured using immunoassays. RESULTS NfL demonstrated fair to excellent accuracy in differentiating non-ACS from CU groups (area under the curve [AUC], 0.79 to 0.94). p-tau217 had the highest accuracy for identifying A beta (AUC 0.94) and tau positron emission tomography status (AUC 0.91). In the ACS group, p-tau217 was the strongest predictor of cognitive decline (p < .001). DISCUSSION NfL may serve as a useful screening tool, while p-tau217 is particularly valuable for confirming AD pathology and prognosis.

引用

页数：12

共 50 条

[1] Biomarker-guided clustering of Alzheimer's disease clinical syndromes
Toschi, Nicola
Lista, Simone
Baldacci, Filippo
Cavedo, Enrica
Zetterberg, Henrik
Blennow, Kaj
Kilimann, Ingo
Teipel, Stefan J.
dos Santos, Antonio Melo
Epelbaum, Stephane
Lamari, Foudil
Genthon, Remy
Habert, Marie-Odile
Dubois, Bruno
Floris, Roberto
Garaci, Francesco
Vergallo, Andrea
Hampel, Harald
Afshar, Mohammad
Aguilar, Lisi Flores
Akman-Anderson, Leyla
Arenas, Joaquin
Babiloni, Claudio
Baldacci, Filippo
Batrla, Richard
Benda, Norbert
Black, Keith L.
Bokde, Arun L. W.
Bonuccelli, Ubaldo
Broich, Karl
Cacciola, Francesco
Caraci, Filippo
Castrillo, Juan
Cavedo, Enrica
Ceravolo, Roberto
Chiesa, Patrizia A.
Corvol, Jean-Christophe
Cuello, Augusto Claudio
Cummings, Jeffrey L.
Depypere, Herman
Dubois, Bruno
Duggento, Andrea
Emanuele, Enzo
Escott-Price, Valentina
Federoff, Howard
Ferretti, Maria Teresa
Fiandaca, Massimo
Frank, Richard A.
Garaci, Francesco
Geerts, Hugo
NEUROBIOLOGY OF AGING, 2019, 83 : 42 - 53
[2] Biomarker-guided drug therapy: personalized medicine for treating Alzheimer's disease
Charvi Syal
Jing Wang
Neural Regeneration Research, 2021, 16 (10) : 2010 - 2011
[3] Biomarker-guided drug therapy: personalized medicine for treating Alzheimer's disease
Syal, Charvi
Wang, Jing
NEURAL REGENERATION RESEARCH, 2021, 16 (10) : 2010 - 2011
[4] A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling
Hampel, H.
O'Bryant, S. E.
Durrleman, S.
Younesi, E.
Rojkova, K.
Escott-Price, V.
Corvol, J-C.
Broich, K.
Dubois, B.
Lista, S.
CLIMACTERIC, 2017, 20 (02) : 107 - 118
[5] Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer's Disease
Hampel, H.
Vergallo, A.
Bonuccelli, U.
Lista, S.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2018, 5 (03): : 160 - 164
[6] Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies
Lyketsos, Constantine G.
Szekely, Christine A.
Mielke, Michelle M.
Rosenberg, Paul B.
Zandi, Peter P.
INTERNATIONAL PSYCHOGERIATRICS, 2008, 20 (05) : 871 - 889
[7] Turning Point towards Blood Biomarker-Guided Targeted Therapy for Precision Medicine in Alzheimer’s Disease
Harald Hampel
A. Vergallo
U. Bonuccelli
S. Lista
The Journal of Prevention of Alzheimer's Disease, 2018, 5 : 160 - 164
[8] Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease
Lista, Simone
Toschi, Nicola
Baldacci, Filippo
Zetterberg, Henrik
Blennow, Kaj
Kilimann, Ingo
Teipel, Stefan J.
Cavedo, Enrica
dos Santos, Antonio Melo
Epelbaum, Stephane
Lamari, Foudil
Dubois, Bruno
Floris, Roberto
Garaci, Francesco
Hampel, Harald
NEUROCHEMISTRY INTERNATIONAL, 2017, 108 : 355 - 360
[9] Alzheimer's Disease Performance of Biomarkers in the Diagnostics
Lichert, Frank
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2016, 84 (08)
[10] Advances in biomarker discovery and diagnostics for alzheimer's disease
Bhatia, Vandana
Chandel, Anjali
Minhas, Yavnika
Kushawaha, Shiv Kumar
NEUROLOGICAL SCIENCES, 2025,

← 1 2 3 4 5 →